Medicines Safety Assurance Tool
The Medicines Safety Assurance Tool (MSAT) is provided as a PDF document for reference. To request the spreadsheet solution of this safety tool, or for more information about this tool, to make a comment, or share a safety issue please contact email@example.com.
The MSAT was developed to improve the management of medicines related risk to patients. It is intended to provide commissioners with a systematic way of identifying and analysing emerging medicines safety issues and engage with providers to reduce medicines related harm.
Transition of Commissioning Policies
On 1st July 2022 NHS Cheshire and Merseyside Integrated Care Board (ICB) became the new statutory body responsible for ensuring health care services are available to meet the reasonable needs of the people of Cheshire & Merseyside.
Until such time as a single suite of commissioning policies can be developed and adopted, NHS Cheshire and Merseyside will continue to adopt and operate the CCG policies it has inherited at Place/borough level, which means that there will be no immediate change in commissioning policy for local people resident in those Places/boroughs from what was in place prior to 1st July 2022.
Service users prescribed clozapine will have it prescribed, monitored, and dispensed via their local mental health trust. Where a service user is under the care of a third party, e.g., during an acute medical admission, this may lead to a break down in care. This guidance is aimed at highlighting these risks and providing solutions for the non specialist.
Codeine is contraindicated in all children aged 0-18 years who undergo tonsillectomy or adenoidectomy (or both) for obstructive sleep apnoea. Codeine is restricted to children over 12 years of age and only if the benefit outweighs the risks.